Monitoring for the Adverse Effects of Drugs

Evidence-based Medical Monitoring: From Principles to Practice

Volumn , Issue , 2008, Pages 194-210

  Coleman, Jamie J E ^a   Ferner, Robin E ^b   Aronson, Jeffrey K ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adverse reaction; Dose relatedness; Drugs; Headache; Pruritus

Indexed keywords

EID: 84889405319     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470696323.ch15     Document Type: Chapter

References (27)

1. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO International Database. Drug Saf 2000; 23: 533-42.
2. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6.
3. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28: 851-70.
4. Ferner RE, Coleman JJ, Pirmohamed M, Constable S, Rouse AR. The quality of information on monitoring for haematological for adverse drug reactions. Br J Clin Pharmacol 2005; 60: 448-51.
5. Pirmohamed M, Ferner RE. Monitoring drug treatment. BMJ 2003; 327: 1179-81.
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
7. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
8. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-8.
9. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5.
10. Wetzels GE, Nelemans PJ, Schouten JS, van Wijk BL, Prins MH. All that glisters is not gold: a comparison of electronic monitoring versus filled prescriptions-an observational study. BMC Health Serv Res 2006; 6: 8.
11. George CF, Peveler RC, Heiliger S, Thompson C. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol 2000; 50: 166-71.
12. Dubbert PM, King A, Rapp SR, Brief D, Martin JE, Lake M. Riboflavin as a tracer of medication compliance. J Behav Med 1985; 8: 287-99.
13. Kumar S, Haigh JR, Rhodes LE, et al. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thromb Haemost 1989; 62: 729-32.
14. Reynolds DJ, Aronson JK. ABC of drug monitoring. Making the most of plasma drug concentration measurements. BMJ 1993; 306: 48-51.
15. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126: 1415-23.
16. Simon CH, Dijkmans BA, Breedveld FC. Variations in the monitoring and management of the side effects of antirheumatic drugs by means of laboratory tests. Clin Exp Rheumatol 1997; 15: 633-9.
17. Russell GI, Bing RF, Jones JA, Thurston H, Swales JD. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype. Q J Med 1987; 65: 845-52.
18. Carstairs KC, Breckenridge A, Dollery CT, Worlledge SM. Incidence of a positive direct Coombs' test in patients on alpha-methyldopa. Lancet 1966; 2: 133-5.
19. Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 2001; 52 (Suppl 1): 21S-34S.
20. Kucher N, Connolly S, Beckman JA, et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med 2004; 164: 2176-9.
21. Alvir JMJ, Lieberman JA, Safferman AZ, Schwinner JL, Schaaf JA. Clozapineinduced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7.
22. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
23. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review. JAMA 2001; 286: 2270-9.
24. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 2004; 58: S867-S871.
25. Armstrong VW, Shipkova M, von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26: 220-6.
26. Coulthard SA, Matheson EC, Hall AG, Hogarth LA. The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1385-91.
27. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 2001; 52 (Suppl 1): 45S-54S.